IL269258A - Methods and compositions for inducing immune responses against clostridium difficile - Google Patents

Methods and compositions for inducing immune responses against clostridium difficile

Info

Publication number
IL269258A
IL269258A IL26925819A IL26925819A IL269258A IL 269258 A IL269258 A IL 269258A IL 26925819 A IL26925819 A IL 26925819A IL 26925819 A IL26925819 A IL 26925819A IL 269258 A IL269258 A IL 269258A
Authority
IL
Israel
Prior art keywords
compositions
methods
immune responses
clostridium difficile
responses against
Prior art date
Application number
IL26925819A
Other languages
Hebrew (he)
Other versions
IL269258B2 (en
IL269258B1 (en
Inventor
Gale Smith
Ye Liu
Jing-Hui Tian
Gregory Glenn
David Flyer
Original Assignee
Novavax Inc
Gale Smith
Ye Liu
Tian jing hui
Gregory Glenn
David Flyer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novavax Inc, Gale Smith, Ye Liu, Tian jing hui, Gregory Glenn, David Flyer filed Critical Novavax Inc
Publication of IL269258A publication Critical patent/IL269258A/en
Publication of IL269258B1 publication Critical patent/IL269258B1/en
Publication of IL269258B2 publication Critical patent/IL269258B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
IL269258A 2017-03-15 2018-03-15 Methods and compositions for inducing immune responses against clostridium difficile IL269258B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762471636P 2017-03-15 2017-03-15
US201762474434P 2017-03-21 2017-03-21
PCT/US2018/022597 WO2018170238A2 (en) 2017-03-15 2018-03-15 Methods and compositions for inducing immune responses against clostridium difficile

Publications (3)

Publication Number Publication Date
IL269258A true IL269258A (en) 2019-11-28
IL269258B1 IL269258B1 (en) 2023-05-01
IL269258B2 IL269258B2 (en) 2023-09-01

Family

ID=63523217

Family Applications (1)

Application Number Title Priority Date Filing Date
IL269258A IL269258B2 (en) 2017-03-15 2018-03-15 Methods and compositions for inducing immune responses against clostridium difficile

Country Status (12)

Country Link
US (2) US11123419B2 (en)
EP (1) EP3595709A4 (en)
JP (2) JP7149285B2 (en)
KR (1) KR102640722B1 (en)
CN (1) CN110691609B (en)
AU (1) AU2018236352B2 (en)
BR (1) BR112019019117A2 (en)
CA (1) CA3056090A1 (en)
IL (1) IL269258B2 (en)
MX (1) MX2019010948A (en)
SG (1) SG11201908376UA (en)
WO (1) WO2018170238A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR122019017005B1 (en) 2011-04-22 2022-03-29 Wyeth Llc Compositions that relate to a mutant Clostridium difficile toxin
BR122016023101B1 (en) 2012-10-21 2022-03-22 Pfizer Inc Polypeptide, immunogenic composition comprising it, as well as recombinant cell derived from Clostridium difficile
WO2018170238A2 (en) 2017-03-15 2018-09-20 Novavax, Inc. Methods and compositions for inducing immune responses against clostridium difficile
EP4168032A2 (en) * 2020-06-19 2023-04-26 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
WO2023232901A1 (en) 2022-06-01 2023-12-07 Valneva Austria Gmbh Clostridium difficile vaccine

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
EP1017743A1 (en) * 1997-09-04 2000-07-12 Eastman Chemical Company Thermoplastic polyurethane additives for enhancing solid state polymerization rates
US20120020996A1 (en) * 2008-08-06 2012-01-26 Jonathan Lewis Telfer Vaccines against clostridium difficile and methods of use
US10046040B2 (en) * 2009-11-16 2018-08-14 University Of Maryland, Baltimore Multivalent live vector vaccine against Clostridium difficile-associated disease
US20130039973A1 (en) * 2011-08-03 2013-02-14 Henry J. Smith Viral Immunogenic Compositions
CN104080476A (en) * 2011-09-30 2014-10-01 诺瓦瓦克斯股份有限公司 Recombinant nanoparticle RSV F vaccine for respiratory syncytial virus
AR089797A1 (en) * 2012-01-27 2014-09-17 Merck Sharp & Dohme VACCINES AGAINST CLOSTRIDUM DIFFICILE THAT INCLUDE RECOMBINANT TOXINS
JP6290918B2 (en) * 2012-12-05 2018-03-07 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Immunogenic composition
GB201223342D0 (en) * 2012-12-23 2013-02-06 Glaxosmithkline Biolog Sa Immunogenic composition
CN105451762A (en) * 2013-04-22 2016-03-30 俄克拉荷马州大学评议会 Clostridium difficile vaccine and methods of use
PL3062815T3 (en) * 2013-11-01 2019-07-31 Pfizer Inc. Vectors for expression of prostate-associated antigens
BE1022949B1 (en) * 2014-06-25 2016-10-21 Glaxosmithkline Biologicals S.A. IMMUNOGENIC COMPOSITION
CN106220737B (en) * 2016-07-21 2020-11-10 中国人民解放军军事医学科学院微生物流行病研究所 Fusion protein and application thereof in treatment of clostridium difficile related diseases
WO2018170238A2 (en) 2017-03-15 2018-09-20 Novavax, Inc. Methods and compositions for inducing immune responses against clostridium difficile

Also Published As

Publication number Publication date
MX2019010948A (en) 2020-01-09
EP3595709A4 (en) 2020-12-23
IL269258B2 (en) 2023-09-01
AU2018236352A1 (en) 2019-10-03
JP2022179543A (en) 2022-12-02
JP7397145B2 (en) 2023-12-12
WO2018170238A3 (en) 2018-10-18
JP2020509770A (en) 2020-04-02
CA3056090A1 (en) 2018-09-20
JP7149285B2 (en) 2022-10-06
RU2019132111A3 (en) 2021-06-29
CN110691609B (en) 2024-04-19
IL269258B1 (en) 2023-05-01
US20220211834A1 (en) 2022-07-07
US11938179B2 (en) 2024-03-26
EP3595709A2 (en) 2020-01-22
KR102640722B1 (en) 2024-02-26
CN110691609A (en) 2020-01-14
RU2019132111A (en) 2021-04-15
SG11201908376UA (en) 2019-10-30
US20200085934A1 (en) 2020-03-19
AU2018236352B2 (en) 2024-04-04
US11123419B2 (en) 2021-09-21
BR112019019117A2 (en) 2020-05-05
WO2018170238A2 (en) 2018-09-20
KR20190125470A (en) 2019-11-06

Similar Documents

Publication Publication Date Title
GB201708444D0 (en) Compositions and methods for inducing an immune response
IL250872B (en) Methods and compositions for attenuating anti-viral transfer vector immune responses
EP3096782A4 (en) Compositions and methods for modulating and redirecting immune responses
IL253341B (en) Methods and compositions for combination immunotherapy
IL250818A0 (en) Methods and compositions for enhancing immune responses
IL269258B1 (en) Methods and compositions for inducing immune responses against clostridium difficile
LT3240895T (en) Compositions and methods for protein glycosylation
IL247614B (en) Methods and compositions for modifying the immune response
IL268684A (en) Compositions and methods for immunooncology
IL246879A0 (en) Apilimod compositions and methods for using same
HK1250637A1 (en) Agents and compositions for eliciting an immune response
HK1245158A1 (en) Apilimod compositions and methods for using same
IL273336A (en) Compositions and methods for eliciting an immune response against clostridium difficile
EP3518976A4 (en) Compositions and methods for improving immune system function
IL266562A (en) Methods and compositions for adaptive immune modulation
IL274524A (en) Compositions and methods for aquaculturing
IL274176A (en) Compositions and methods for enhancing visual function
IL283299A (en) Compositions and methods for immune tolerance
SG11201706514VA (en) Method and apparatus for testing immune state
EP3097420A4 (en) Methods and compositions for immune dis-inhibition
IL265965A (en) Methods and compositions for tusc2 immunotherapy
GB201705626D0 (en) Compositions and methods
GB201807932D0 (en) Compositions and methods for inducing an immune response
ZA201807665B (en) Methods and compositions
GB201715820D0 (en) Compositions and methods